Abstract
The t(4:14) translocation affects two potential oncogenes, FGFR3 and MMSET, in multiple myeloma (MM). We investigated the frequency of FGFR3 dysregulation and its prognostic value in MM. FGFR3 mRNA levels were determined in 110 diagnostic bone marrow (BM) samples from MM patients. In addition, selected BM samples were screened for elevated MMSET mRNA levels. 14.5% (16/110) of MM BM samples showed dysregulated FGFR3 expression. Follow-up of 76 MM patients showed no significant difference between FGFR3 dysfunction and survival (P = 0.3) or correlation with known prognostic factors. Further, no linear relation was observed between FGFR3 and MMSET levels.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Biomarkers, Tumor / genetics*
-
Carrier Proteins*
-
Female
-
Fibroblast Growth Factors / genetics
-
Follow-Up Studies
-
Gene Expression Regulation, Neoplastic*
-
High Mobility Group Proteins / genetics
-
Histone-Lysine N-Methyltransferase
-
Humans
-
Male
-
Multiple Myeloma / genetics*
-
Neoplasm Proteins / genetics
-
Prognosis
-
Protein-Tyrosine Kinases*
-
RNA, Messenger / genetics
-
RNA, Neoplasm / genetics
-
Receptor, Fibroblast Growth Factor, Type 3
-
Receptors, Fibroblast Growth Factor / genetics*
-
Repressor Proteins*
-
Survival Rate
Substances
-
Biomarkers, Tumor
-
Carrier Proteins
-
High Mobility Group Proteins
-
Neoplasm Proteins
-
RNA, Messenger
-
RNA, Neoplasm
-
Receptors, Fibroblast Growth Factor
-
Repressor Proteins
-
Fibroblast Growth Factors
-
Histone-Lysine N-Methyltransferase
-
NSD2 protein, human
-
FGFR3 protein, human
-
Protein-Tyrosine Kinases
-
Receptor, Fibroblast Growth Factor, Type 3